查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1997341

临床试验影像市场：依服务类型、影像方式、最终使用者和治疗领域划分－2026-2032年全球市场预测

Clinical Trial Imaging Market by Offerings, Modality, End-User, Therapeutic area - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，临床试验影像市场价值将达到 16.1 亿美元，到 2026 年将成长到 17.2 亿美元，到 2032 年将达到 28.3 亿美元，复合年增长率为 8.42%。

主要市场统计数据
基准年 2025 16.1亿美元
预计年份：2026年 17.2亿美元
预测年份 2032 28.3亿美元
复合年增长率 (%) 8.42%

简要概述临床试验影像如何发展成为一项综合策略功能，从而加快通讯协定决策并增强监管机构的信心。

临床试验影像已发展成为现代药物研发的战略支柱，它整合了先进的成像方式、分析技术和操作流程，以支持客观终点、安全性监测和患者分层。近年来，影像已不再只是辅助测量工具，而是成为通讯协定设计、适应性试验策略和监管沟通的关键要素。这种转变既反映了影像撷取硬体的技术进步，也反映了能够整合来自多个中心和供应商的异质影像资料集的软体工具的同步发展。

技术融合、监管认可和不断发展的营运模式如何重塑临床试验成像生态系统和决策流程。

临床试验影像领域正经历一场变革，其驱动力包括技术融合、监管机构对客观终点指标的重视以及不断演进的营运模式。人工智慧 (AI) 和先进的分析技术透过提供自动分割、定量生物标记提取和异常检测，对传统的放射学评估进行了补充，从而降低了变异性并提高了对治疗效果的敏感性。随着这些功能的日益普及，申办者和影像服务供应商正在采用混合工作流程，将自动预处理与盲法专家解读相结合，以确保临床有效性。

近期关税调整对医疗影像专案的设备分配、供应商选择和供应链弹性产生了影响，需要考虑实际因素和营运调整。

近期某些地区针对医疗设备、组件及相关服务征收的关税，为临床试验影像服务带来了新的考量，尤其是在依赖跨境运输扫描仪、配件和专用硬体的全球性试验中。关税带来的成本压力会影响设备采购时机、维护计画以及现场服务与集中服务的选择。实际上，申办者和影像服务供应商正在权衡各种方案，例如本地采购设备、将影像解读外包给区域核心检查室，或利用云端分析来最大限度地减少实体运输。

基于细分的详细洞察，使产品和服务、成像方式、治疗重点和最终用户期望与营运和临床要求保持一致。

以细分市场为重点的分析揭示了产品和服务、成像方式、治疗领域和最终用户类别中清晰的优先事项和营运需求。基于产品和服务，市场研究团队将市场分为「服务」和「软体」两大类，「服务」进一步细分为「影像操作服务」、「影像解读和分析服务」、「系统和技术支援服务」以及「临床实验设计和咨询服务」。这种细分凸显了客户通常会购买捆绑式服务模式，将现场支援和集中分析相结合，以确保其全球各地服务的一致性。基于影像方式，研究范围涵盖电脑断层扫描 (CT)、心臟超音波图、磁振造影(MRI)、正子断层扫描 (PET)、超音波和放射成像，每种影像方式都有其独特的成像通讯协定、品管和分析需求，这些都会影响供应商的选择和培训要求。

主要全球区域的区域基础设施、监管多样性和营运能力对临床试验影像策略和实施的影响。

区域趋势对诊断影像实践、供应商生态系统和监管合作有显着影响，在能力、基础设施和合作网络方面呈现出明显的区域格局。在美洲，先进的诊断影像基础设施、众多核心影像实验室和广泛应用的数位化工作流程为复杂的多中心临床试验提供了支援。然而，营运挑战依然存在，包括地理距离、各中心能力差异以及在不同的临床环境中实现严格标准化的必要性。因此，申办方往往倾向于采用集中式影像判读结合区域技术支援的模式，以平衡品质和物流。

竞争格局洞察显示专业供应商、软体创新者、核心实验室和 CRO 联盟如何为试验建立差异化的端到端成像解决方案。

临床试验影像领域的竞争格局反映了专业服务供应商、软体创新者、影像核心实验室和整合供应商联盟的整合，从而塑造了服务交付模式。领先的影像机构透过提供检验的影像解读平台、特定模态的专业知识以及咨询式试验设计服务来脱颖而出，帮助申办方将临床假设转化为可靠的影像终点。同时，提供可扩展分析、安全云端储存和符合监管要求的审计追踪的软体公司在多供应商合作和资料管治中扮演着日益重要的角色。

影像专案的领导者将互通性、检验的分析和早期通讯协定调整相结合，以实施可操作的策略措施，从而降低试验风险并提高资料效用。

产业领导者应采取策略性方法，整合技术投资、严格的营运规范和合作伙伴关係，以提升临床试验影像计画的有效性。首先，应优先考虑互通性，选择支援标准化影像通讯协定和安全性、检验资料传输的平台和供应商。此类选择可减少下游流程的差异，并有助于总结分析。其次，应引入自动化分析，以辅助专家解读，利用已验证的演算法加速预处理，标示品质问题，并维持最终终点判定的盲法性。

采用严谨的混合方法，结合相关人员访谈、二手证据整合和资料检验，以确保对诊断影像提供可靠且可操作的见解。

本研究采用混合方法，以确保研究的严谨性、可重复性和对决策者的相关性。该方法结合了对行业相关人员（包括影像科负责人、临床运营负责人和科学顾问）的调查方法，以及对公开的监管指南、临床试验註册数据、技术白皮书和同行评审文献的全面二次分析。主要访谈着重于营运挑战、供应商选择标准、特定成像方式的考量以及区域实施瓶颈，从而为二次分析结果提供了实证观点。

总结了综合成像策略、检验的分析方法和操作弹性如何决定临床试验的成功和证据的可靠性。

临床试验影像已成为实证医学的核心，它提供客观且可重复的测量结果，为临床决策和监管对话提供支援。先进成像技术、自动化分析和整合服务模式的结合，能够提高终点敏感度、降低变异性并加快获得有意义结果的速度。同时，影像技术异质性、区域差异以及不断变化的业务需求所带来的营运复杂性，也要求我们进行周密的规划、供应商管治以及对可互操作系统进行投资。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 临床试验影像市场：依产品/服务分类

  • 服务
    • 影像处理操作服务
    • 影像分析服务
    • 系统和技术支援服务
    • 临床实验设计与咨询服务
  • 软体
  • 硬体

第九章 临床试验影像市场：依影像方式划分

  • 电脑断层扫描
  • 心臟超音波图
  • 磁振造影
  • 正子断层扫描
  • 超音波
  • X射线

第十章 临床试验影像市场：依最终使用者划分

  • 学术和政府附属研究机构
  • 生技公司
  • 合约研究机构
  • 製药公司

第十一章 临床试验影像市场：依治疗领域划分

  • 内分泌学
  • 免疫疾病
  • 感染疾病
  • 神经病学
  • 肿瘤学

第十二章 临床试验影像市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 临床试验影像市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 临床试验影像市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国临床试验影像市场

第十六章：中国临床试验影像市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Alimentiv Inc.
  • Anagram 4 Clinical Trials
  • Biospective Inc.
  • BioTelemetry, Inc.
  • Boston Imaging Core Lab LLC
  • Cardiovascular Imaging Technologies LLC
  • Clario
  • GE HealthCare Technologies Inc.
  • Icon PLC
  • Image Analysis Ltd
  • Image Core Lab Private Limited
  • Imaging Endpoints II LLC
  • Invicro, LLC
  • Ixico PLC
  • Median Technologies
  • Medical Metrics Inc. by Catalent, Inc.
  • Medidata by Dassault Systemes
  • Medpace, Inc.
  • Micron Inc.
  • Mint Medical GmbH
  • Navitas Life Sciences
  • Parexel International Corporation
  • Perceptive Informatics LLC
  • Perspectum Ltd
  • Prism Clinical Imaging, Inc.
  • ProScan Imaging LLC
  • Quotient Sciences Limited
  • Radiant Sage LLC
  • Resonance Health Ltd.
  • Voiant Clinical
  • WCG Clinical, Inc.
Product Code: MRR-501246435DF5

The Clinical Trial Imaging Market was valued at USD 1.61 billion in 2025 and is projected to grow to USD 1.72 billion in 2026, with a CAGR of 8.42%, reaching USD 2.83 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.61 billion
Estimated Year [2026] USD 1.72 billion
Forecast Year [2032] USD 2.83 billion
CAGR (%) 8.42%

A concise orientation to how clinical trial imaging has evolved into an integrated, strategic capability that accelerates protocol decisions and regulatory confidence

Clinical trial imaging has matured into a strategic pillar of contemporary drug development, integrating advanced modalities, analytics, and operational workflows to support objective endpoints, safety monitoring, and patient stratification. Over recent years, imaging has expanded beyond a supporting measurement to become a decisive element in protocol design, adaptive trial strategies, and regulatory interactions. This shift reflects both technological advancements in acquisition hardware and the parallel evolution of software tools capable of harmonizing heterogeneous imaging datasets across sites and vendors.

As a result, sponsors and trial operators increasingly prioritize imaging strategy at earlier stages of study planning. Cross-functional teams now coordinate imaging logistics, vendor selection, quality assurance, and data governance in tandem with biostatistics and clinical operations, thereby reducing rework and accelerating readouts. Consequently, a layered approach to imaging-encompassing modality selection, centralized reading paradigms, and integrated analytics-has emerged as best practice where reproducibility and interpretability are critical.

Transitioning from isolated imaging tasks to a unified imaging program requires deliberate change management, investment in vendor oversight, and the adoption of interoperable systems. When executed well, these investments yield more defensible endpoints, streamlined regulatory submissions, and enhanced confidence across stakeholder groups, including clinical investigators and regulatory reviewers. The remainder of this executive summary explores the forces reshaping the landscape, tariff implications, segmentation-driven insights, regional dynamics, competitive activity, actionable recommendations, methodological rigor, and an invitation to procure the full report for deeper guidance.

How converging technologies, regulatory acceptance, and evolving operational models are reshaping the clinical trial imaging ecosystem and decision pathways

The clinical trial imaging landscape is experiencing transformative shifts driven by technology convergence, regulatory emphasis on objective endpoints, and evolving operational models. Artificial intelligence and advanced analytics now complement traditional radiologic assessment by offering automated segmentation, quantitative biomarker extraction, and anomaly detection that decrease variability and enhance sensitivity to treatment effects. As these capabilities become more accessible, sponsors and imaging service providers are adopting hybrid workflows that blend automated pre-processing with blinded expert reads to maintain clinical validity.

Concurrently, regulatory authorities have signaled greater receptivity to imaging-derived endpoints when supported by standardized acquisition and validated analytic pipelines, prompting sponsors to embed imaging strategy earlier in the protocol lifecycle. This regulatory receptivity encourages investments in imaging core labs, centralized reading models, and rigorous quality assurance frameworks. Operationally, there is a pronounced movement toward vendor consolidation and platform unification to reduce complexity and improve data traceability across multi-center, global trials.

Finally, payer and health economics stakeholders increasingly evaluate the real-world applicability of imaging biomarkers, which is influencing endpoint selection and long-term evidence plans. Together, these shifts compel organizations to reassess capabilities, prioritize interoperable systems, and cultivate partnerships that accelerate deployment of robust imaging programs aligned to clinical and commercial objectives.

Practical considerations and operational adaptations driven by recent tariff adjustments that affect equipment flows, vendor selection, and supply chain resilience for imaging programs

The recent imposition of tariffs affecting medical equipment, components, and associated services in some jurisdictions has introduced new considerations for clinical trial imaging operations, particularly in global studies that rely on cross-border shipment of scanners, accessories, and specialized hardware. Tariff-related cost pressures can influence timing for equipment procurement, maintenance scheduling, and decisions around on-site versus centralized services. In practice, sponsors and imaging service organizations evaluate the trade-offs between procuring equipment locally, outsourcing imaging reads to regional core labs, or leveraging cloud-hosted analytics to minimize physical transfers.

In response, many stakeholders have explored localized sourcing strategies and negotiated longer-term service agreements to stabilize total cost of ownership while preserving data quality and regulatory compliance. This strategy reduces the frequency of cross-border movements of capital equipment and emphasizes partnerships with regional vendors that can provide timely technical support and adherence to standardized acquisition protocols. Moreover, shifts in supply chain routing have encouraged closer collaboration between procurement, clinical operations, and vendor management teams to ensure continuity of imaging capacity for ongoing trials.

Importantly, organizations are also reviewing contracting terms to include tariff contingency clauses and flexible service-level agreements that account for potential trade disruptions. While tariff measures introduce complexity, they also motivate more resilient operational planning, diversified supplier networks, and greater emphasis on in-region capabilities that can safeguard trial timelines and data integrity.

Detailed segmentation-driven insights that align product/service offerings, imaging modalities, therapeutic priorities, and end-user expectations to operational and clinical requirements

Segment-focused analysis reveals distinct priorities and operational requirements across the product and service continuum, modalities, therapeutic areas, and end-user categories. Based on Product & Service, market study groups Services and Software, where Services is further clarified into Operational Imaging Services, Read Analysis Services, System & Technical Support Services, and Trial Design & Consulting Services; this segmentation highlights that clients often purchase bundled service models that combine hands-on site support with centralized analytics to maintain consistency across global sites. Based on Modality, the landscape encompasses Computed Tomography, Echocardiography, Magnetic Resonance Imaging, Positron Emission Tomography, Ultrasound, and X-Ray, each modality presenting unique acquisition protocols, quality controls, and analytic needs that affect vendor selection and training requirements.

Therapeutic nuance matters as well; based on Therapeutic area, studies span Endocrinology, Immunological Disorder, Infectious Diseases, Neurology, and Oncology, with oncology trials frequently demanding multi-parametric imaging and longer follow-up while neurology trials emphasize standardized cognitive and structural imaging endpoints. Based on End-User, the ecosystem includes Academic & Government Research Institutes, Biotechnology Companies, Contract Research Organizations, and Pharmaceutical Companies, where each end-user brings its own procurement cadence, regulatory expectations, and appetite for innovation. For instance, academic centers may prioritize methodological rigor and novel biomarkers, whereas commercial sponsors often emphasize scalability, cost predictability, and time to readout.

Taken together, these segmentation vectors underscore the importance of flexible service architectures, modality-specific standard operating procedures, and targeted client engagement models that align technical capabilities with therapeutic intent and end-user requirements. Strategic vendors and sponsors that tailor their offerings across these dimensions achieve higher operational efficiency and better alignment with trial goals.

How regional infrastructure, regulatory diversity, and operational capacity across major global regions influence clinical trial imaging strategy and execution

Regional dynamics exert a material influence on imaging operations, vendor ecosystems, and regulatory interactions, with distinct regional patterns in capacity, infrastructure, and collaborative networks. In the Americas, advanced imaging infrastructure, a large base of imaging core laboratories, and high adoption of digital workflows support complex, multi-center trials; however, operational challenges include geographic distances, variable site capabilities, and the need for robust standardization across heterogeneous clinical settings. Consequently, sponsors often favor centralized reading combined with regional technical support to balance quality and logistics.

In Europe, Middle East & Africa, regulatory diversity and variable imaging infrastructure necessitate meticulous harmonization of protocols, translation of standard operating procedures across languages, and careful site qualification processes. The region benefits from strong academic centers and established collaborative research networks, which facilitate multi-country studies if sponsors invest in upfront training and platform interoperability. In addition, regional vendors often provide valuable localized technical support and faster equipment deployment timelines.

In Asia-Pacific, rapid investments in imaging hardware, expanding clinical research capacity, and growing local CRO capabilities have increased the region's appeal for large-scale trials. Nevertheless, differences in clinical practice patterns, data protection frameworks, and modality penetration require tailored imaging strategies that emphasize early site assessment and scalable cloud-based solutions. Across all regions, success depends on proactive local engagement, standardized acquisition protocols, and robust QA programs that bridge regional variability and preserve data integrity for pooled analyses.

Competitive landscape insights showing how specialized providers, software innovators, core labs, and CRO alliances create differentiated end-to-end imaging solutions for trials

Competitive dynamics in clinical trial imaging reflect a blend of specialized service providers, software innovators, imaging core labs, and integrated vendor alliances that together shape service delivery models. Leading imaging organizations differentiate by offering validated reading platforms, modality-specific expertise, and consultative trial design services that help sponsors translate clinical hypotheses into robust imaging endpoints. At the same time, software companies that deliver scalable analytics, secure cloud storage, and regulatory-grade audit trails are increasingly central to multi-vendor orchestration and data governance.

Partnerships between imaging services and technology firms are common, enabling an end-to-end proposition that combines site training, centralized reads, and advanced post-processing. Contract Research Organizations expand their portfolios by incorporating imaging capabilities either organically or through strategic alliances, thereby offering sponsors single-vendor solutions that streamline vendor management. Academic centers and specialty research institutes continue to contribute methodological innovation and validation studies that inform best practices and regulatory dialogue.

For purchasers, competitive evaluation should prioritize demonstrated modality experience, validated analytic pipelines, regulatory compliance history, and the operational capacity to support global trials. Vendors that can demonstrate cross-modal interoperability, transparent quality metrics, and customizable service tiers generally hold a competitive edge. Ultimately, the market favors collaborators who can reduce complexity, provide traceable audit trails, and align technical delivery with clinical objectives.

Actionable strategic moves for imaging program leaders to integrate interoperability, validated analytics, and early protocol alignment to de-risk trials and enhance data utility

Industry leaders should adopt a strategic posture that integrates technological investment, operational rigor, and collaborative partnerships to elevate the effectiveness of clinical trial imaging programs. First, prioritize interoperability by selecting platforms and vendors that support standardized acquisition protocols and secure, auditable data transfer; such choices reduce downstream variability and facilitate pooled analyses. Second, incorporate automated analytics as a complement to expert reads, using validated algorithms to accelerate pre-processing and flag quality issues while preserving blinded adjudication for final endpoint determination.

Next, invest in early-stage imaging strategy development by embedding imaging experts in protocol design to align modality selection, timing of scans, and read paradigms with clinical endpoints and regulatory expectations. This approach minimizes rework and mitigates the risk of unreadable or unusable imaging data. Additionally, cultivate regional supplier networks and flexible contracting terms that account for tariff-related contingencies and localized equipment support, ensuring continuity of imaging capacity across diverse geographies. Finally, establish transparent quality metrics, regular cross-site calibration exercises, and governance mechanisms that assign clear accountability for imaging deliverables. By implementing these measures, sponsors and service providers can reduce operational friction, enhance data integrity, and accelerate the translational value of imaging within clinical programs.

A rigorous mixed-methods approach combining stakeholder interviews, secondary evidence synthesis, and data triangulation to ensure reliable and actionable imaging insights

This research employed a mixed-methods approach to ensure rigor, reproducibility, and relevance for decision-makers. The methodology combined primary qualitative engagement with industry stakeholders, including imaging directors, clinical operations leads, and scientific advisors, with comprehensive secondary analysis of publicly available regulatory guidance, clinical trial registries, technical white papers, and peer-reviewed literature. Primary interviews focused on operational challenges, vendor selection criteria, modality-specific considerations, and regional execution bottlenecks, providing grounded perspectives that contextualize secondary findings.

Data triangulation was applied throughout to validate themes and reconcile divergent viewpoints. The research team synthesized procedural standards, technical specifications, and real-world implementation lessons to produce actionable recommendations. Quality assurance procedures included cross-validation of interview transcripts, consistency checks across data sources, and peer review by domain experts to ensure the reliability of analytical conclusions. Where applicable, methodological caveats and assumptions were documented to help readers interpret findings in light of study scope and the evolving regulatory and technological environment.

Finally, the approach emphasized transparency in data provenance and interpretive steps, enabling readers to trace conclusions back to source inputs and understand how operational realities and technological innovations informed the analytic framework.

Concluding synthesis of how integrated imaging strategy, validated analytics, and operational resilience together determine trial success and evidence credibility

Clinical trial imaging now occupies a central role in the evidence generation pathway, offering objective, reproducible measures that support clinical decision-making and regulatory dialogue. The interplay of advanced modalities, automated analytics, and integrated service models creates opportunities to enhance endpoint sensitivity, reduce variability, and accelerate time to meaningful readouts. At the same time, operational complexity-driven by modality heterogeneity, regional differences, and evolving trade considerations-demands deliberate planning, vendor governance, and investment in interoperable systems.

Looking ahead, organizations that prioritize early integration of imaging strategy into protocol design, adopt validated analytics responsibly, and cultivate resilient supplier networks will be better positioned to harness imaging as a strategic differentiator. In parallel, rigorous quality assurance, transparent performance metrics, and close collaboration with regulatory and scientific stakeholders will remain essential to translating imaging data into credible clinical evidence. Collectively, these actions will strengthen the role of imaging across therapeutic areas and end-users, delivering clearer, more reliable outcomes for both clinical programs and broader health system stakeholders.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Clinical Trial Imaging Market, by Offerings

  • 8.1. Services
    • 8.1.1. Operational Imaging Services
    • 8.1.2. Read Analysis Services
    • 8.1.3. System & Technical Support Services
    • 8.1.4. Trial Design & Consulting Services
  • 8.2. Software
  • 8.3. Hardware

9. Clinical Trial Imaging Market, by Modality

  • 9.1. Computed Tomography
  • 9.2. Echocardiography
  • 9.3. Magnetic Resonance Imaging
  • 9.4. Positron Emission Tomography
  • 9.5. Ultrasound
  • 9.6. X-Ray

10. Clinical Trial Imaging Market, by End-User

  • 10.1. Academic & Government Research Institutes
  • 10.2. Biotechnology Companies
  • 10.3. Contract Research Organizations
  • 10.4. Pharmaceutical Companies

11. Clinical Trial Imaging Market, by Therapeutic area

  • 11.1. Endocrinology
  • 11.2. Immunological Disorder
  • 11.3. Infectious Diseases
  • 11.4. Neurology
  • 11.5. Oncology

12. Clinical Trial Imaging Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Clinical Trial Imaging Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Clinical Trial Imaging Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Clinical Trial Imaging Market

16. China Clinical Trial Imaging Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Alimentiv Inc.
  • 17.6. Anagram 4 Clinical Trials
  • 17.7. Biospective Inc.
  • 17.8. BioTelemetry, Inc.
  • 17.9. Boston Imaging Core Lab LLC
  • 17.10. Cardiovascular Imaging Technologies LLC
  • 17.11. Clario
  • 17.12. GE HealthCare Technologies Inc.
  • 17.13. Icon PLC
  • 17.14. Image Analysis Ltd
  • 17.15. Image Core Lab Private Limited
  • 17.16. Imaging Endpoints II LLC
  • 17.17. Invicro, LLC
  • 17.18. Ixico PLC
  • 17.19. Median Technologies
  • 17.20. Medical Metrics Inc. by Catalent, Inc.
  • 17.21. Medidata by Dassault Systemes
  • 17.22. Medpace, Inc.
  • 17.23. Micron Inc.
  • 17.24. Mint Medical GmbH
  • 17.25. Navitas Life Sciences
  • 17.26. Parexel International Corporation
  • 17.27. Perceptive Informatics LLC
  • 17.28. Perspectum Ltd
  • 17.29. Prism Clinical Imaging, Inc.
  • 17.30. ProScan Imaging LLC
  • 17.31. Quotient Sciences Limited
  • 17.32. Radiant Sage LLC
  • 17.33. Resonance Health Ltd.
  • 17.34. Voiant Clinical
  • 17.35. WCG Clinical, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CLINICAL TRIAL IMAGING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CLINICAL TRIAL IMAGING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY OFFERINGS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES CLINICAL TRIAL IMAGING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA CLINICAL TRIAL IMAGING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY OPERATIONAL IMAGING SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY OPERATIONAL IMAGING SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY OPERATIONAL IMAGING SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY READ ANALYSIS SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY READ ANALYSIS SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY READ ANALYSIS SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY SYSTEM & TECHNICAL SUPPORT SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY SYSTEM & TECHNICAL SUPPORT SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY SYSTEM & TECHNICAL SUPPORT SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY TRIAL DESIGN & CONSULTING SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY TRIAL DESIGN & CONSULTING SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY TRIAL DESIGN & CONSULTING SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY HARDWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY HARDWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY HARDWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ECHOCARDIOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ECHOCARDIOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ECHOCARDIOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ULTRASOUND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY X-RAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY X-RAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY X-RAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ENDOCRINOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ENDOCRINOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ENDOCRINOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY IMMUNOLOGICAL DISORDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY IMMUNOLOGICAL DISORDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY IMMUNOLOGICAL DISORDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS CLINICAL TRIAL IMAGING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS CLINICAL TRIAL IMAGING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE CLINICAL TRIAL IMAGING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST CLINICAL TRIAL IMAGING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. ASEAN CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. ASEAN CLINICAL TRIAL IMAGING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 125. ASEAN CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 127. ASEAN CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 128. ASEAN CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 129. GCC CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GCC CLINICAL TRIAL IMAGING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 131. GCC CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 132. GCC CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 133. GCC CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 134. GCC CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPEAN UNION CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPEAN UNION CLINICAL TRIAL IMAGING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPEAN UNION CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPEAN UNION CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPEAN UNION CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 141. BRICS CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. BRICS CLINICAL TRIAL IMAGING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 143. BRICS CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 144. BRICS CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 145. BRICS CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 146. BRICS CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 147. G7 CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. G7 CLINICAL TRIAL IMAGING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 149. G7 CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 150. G7 CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 151. G7 CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 152. G7 CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 153. NATO CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. NATO CLINICAL TRIAL IMAGING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 155. NATO CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 156. NATO CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 157. NATO CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 158. NATO CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL CLINICAL TRIAL IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. UNITED STATES CLINICAL TRIAL IMAGING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 161. UNITED STATES CLINICAL TRIAL IMAGING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 162. UNITED STATES CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 163. UNITED STATES CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 164. UNITED STATES CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 165. UNITED STATES CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 166. CHINA CLINICAL TRIAL IMAGING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 167. CHINA CLINICAL TRIAL IMAGING MARKET SIZE, BY OFFERINGS, 2018-2032 (USD MILLION)
  • TABLE 168. CHINA CLINICAL TRIAL IMAGING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 169. CHINA CLINICAL TRIAL IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 170. CHINA CLINICAL TRIAL IMAGING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 171. CHINA CLINICAL TRIAL IMAGING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)